SCHEMBL2198983

SCHEMBL2198983

CCOC(=O)C1CN(CC(C)(C)O)CC1c1ccc(Br)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 1/20 0.43
▸ SLC18A2 Q05940 9/20 0.40
▸ SLC6A3 Q01959 4/20 0.40
▸ TSHR P16473 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ HTR2A P28223 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ PDE4A P27815 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7902647 0.88 SLC18A2 (0.38) SLC18A2SLC6A3HTR2APDE4APDE4B
SCHEMBL2198153 0.88 SLC18A2 (0.43) RORCSLC18A2SLC6A3TSHRHTT
SCHEMBL2199609 0.82 SLC6A3 (0.47) RORCSLC18A2SLC6A3TSHRHTT
SCHEMBL2198761 0.82 HTT (0.41) SLC18A2SLC6A3TSHRHTTMEN1
SCHEMBL2762408 0.82 SLC18A2 (0.44) RORCSLC18A2SLC6A3HTR2A
SCHEMBL2197844 0.81 SLC6A3 (0.43) RORCSLC18A2SLC6A3TSHRHTT
SCHEMBL2197505 0.81 RORC (0.68) RORCSLC18A2SLC6A3HTR2A
SCHEMBL2198121 0.80 TSHR (0.44) SLC6A3TSHRHTT
SCHEMBL14276807 0.80 TSHR (0.44) SLC6A3TSHRHTT
SCHEMBL2195172 0.78 MEN1 (0.44) SLC6A3TSHRHTTMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977372-B2 Ortho aminoamides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2011-07-12 — — US disclosed
US-7977372-B2 Ortho aminoamides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2011-07-12 — — US disclosed
US-7977372-B2 Ortho aminoamides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2011-07-12 — — US disclosed
WO-2010094678-A1 NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 — — WO disclosed
US-20100216806-A1 ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE, INC. 2010-08-26 — — US disclosed
US-20100216806-A1 ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE, INC. 2010-08-26 — — US disclosed
US-20100216806-A1 ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE, INC. 2010-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216806-A1 ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER HDAC5, HDAC1, HDAC4 RORC 1997/4885SLC18A2 2805/4885SLC6A3 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback